Literature DB >> 26291699

Concomitant colonic disease (Montreal L3) and re-resectional surgery are predictors of clinical recurrence following ileocolonic resection for Crohn's disease.

P S Morar1,2, O Faiz1,2, J D Hodgkinson1, N Zafar1, K Koysombat2, M Purcell1, A Hart1,2, J Warusavitarne1,2.   

Abstract

AIM: Ileocolonic resection is reserved for patients with moderate to severe Crohn's disease. Postoperative clinical recurrence can occur in up to 55% of patients within 5 years. Predicting the risk of recurrence is key in deciding upon appropriate treatment strategies. This study aims to determine the incidence of postoperative clinical recurrence and predictors of recurrence in a specialist institution.
METHOD: The clinical case records of 142 patients who underwent either a one-stage or two-stage procedure for ileocolonic Crohn's disease from 1 January 2005 to 31 December 2010 were reviewed. Preoperative, perioperative and postoperative variables were extracted. Postoperative clinical recurrence was defined as an initiation or change in medical treatment for recurrent symptoms with endoscopic or radiological evidence of active disease. Time to clinical recurrence was measured in months after surgery. Univariate and multivariate analyses were performed.
RESULTS: Over the 6-year period, follow-up data were obtained on 142 patients over a median of 28.5 months. Clinical recurrence was demonstrated in 59 (41.5%) patients. The proportion of patients with clinical recurrence at 5 years was 48.2%. Predictors of recurrence included a re-resection for recurrent disease [hazard ratio (HR) 1.9; 95% CI 1.1-3.3; P = 0.02] and ileocolonic disease (HR 1.7; 95% CI 1.0-2.9; P = 0.05).
CONCLUSION: Identifying the predictors for postoperative clinical recurrence is important for determining the postoperative strategy. This study provides a unique perspective on the incidence of recurrence and associated predictors from the perspective of a specialist unit. Colorectal Disease
© 2015 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Crohn's disease; clinical recurrence; ileocolonic resection

Mesh:

Year:  2015        PMID: 26291699     DOI: 10.1111/codi.13094

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

1.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.

Authors:  Shirley Cohen-Mekelburg; Stephanie Gold; Yecheskel Schneider; Madison Dennis; Clara Oromendia; Heather Yeo; Fabrizio Michelassi; Ellen Scherl; Adam Steinlauf
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

2.  Establishing Key Performance Indicators [KPIs] and Their Importance for the Surgical Management of Inflammatory Bowel Disease-Results From a Pan-European, Delphi Consensus Study.

Authors:  Pritesh S Morar; James Hollingshead; Willem Bemelman; Nick Sevdalis; Thomas Pinkney; Graeme Wilson; Malcolm Dunlop; R Justin Davies; Richard Guy; Nicola Fearnhead; Steven Brown; Janindra Warusavitarne; Cathryn Edwards; Omar Faiz
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

3.  Risk Factors for Postoperative Recurrence in Korean Patients with Crohn's Disease.

Authors:  Sung Bae Kim; Jae Hee Cheon; Jae Jun Park; Eun Soo Kim; Seong Woo Jeon; Sung-Ae Jung; Dong Il Park; Chang Kyun Lee; Jong Pil Im; You Sun Kim; Hyun Soo Kim; Jun Lee; Chang Soo Eun; Jeong Mi Lee; Byung Ik Jang; Geom Seog Seo
Journal:  Gut Liver       Date:  2020-05-15       Impact factor: 4.519

4.  Characterization of Crohn's disease patients in Egypt: Risk factors for postoperative recurrence (A cohort study).

Authors:  Shimaa Kamel; Mohamed Sakr; Waleed Hamed; Mohamed Eltabbakh; Ahmed Sherief; Heba Rashad; Yasser Elghamrini; Ahmed Elbaz
Journal:  Ann Med Surg (Lond)       Date:  2021-09-06

Review 5.  Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors.

Authors:  Antonios Gklavas; Dionysios Dellaportas; Ioannis Papaconstantinou
Journal:  Ann Gastroenterol       Date:  2017-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.